India hoping to benefit from Novartis 4,000 job shuffle
This article was originally published in Scrip
Novartis's recently announced job cut and transfer plan could result in a flow of openings in India, as part of the company's larger effort to rein in costs and reallocate resources as it gears up for product launches and growth this year.
You may also be interested in...
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.